# HR070803 in Combination With Oxaliplatin, 5-fluorouracil/LV Versus GX as Adjuvant Therapy for Pancreatic Cancer

> **NCT06217042** · PHASE3 · NOT_YET_RECRUITING · sponsor: **Fudan University** · enrollment: 524 (estimated)

## Conditions studied

- Pancreatic Cancer

## Interventions

- **DRUG:** HR070803; Oxaliplatin; 5Fluorouracil; Calcium folinate
- **DRUG:** gemcitabine; capecitabine

## Key facts

- **NCT ID:** NCT06217042
- **Lead sponsor:** Fudan University
- **Sponsor class:** OTHER
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** NOT_YET_RECRUITING
- **Start date:** 2024-02-05
- **Primary completion:** 2027-03-30
- **Final completion:** 2028-07-30
- **Target enrollment:** 524 (ESTIMATED)
- **Last updated:** 2024-01-22


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT06217042

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT06217042, "HR070803 in Combination With Oxaliplatin, 5-fluorouracil/LV Versus GX as Adjuvant Therapy for Pancreatic Cancer". Retrieved via AI Analytics 2026-05-28 from https://api.ai-analytics.org/clinical/NCT06217042. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*